A Phase 3 interventional study of Xeomin and Placebo in Chronic Migraine, sponsored by Merz Therapeutics GmbH. Active, not recruiting at 111 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Merz Therapeutics GmbH (part of Merz Pharma) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing botulinum toxin type A in Migraine Disorders — 6 open to participants now, 10 under way, 5 of them phase 3. botulinum toxin type A · Migraine Disorders.
Among the 39 studies testing botulinum toxin type A in Migraine Disorders, this one is the 2nd largest by enrollment, is one of 3 that started in 2025, is one of 13 in phase 3, and was the 35th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →6 of the 39 studies testing botulinum toxin type A in Migraine Disorders are open now, in 2 countries. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 18–65
Naval Medical Center Camp Lejeune · Sites in United States
Ages 18–89
Assiut University
Ages 18–65
Assiut University
Ages 18–65
Beni-Suef University · Sites in Egypt
Ages 18+
By country, each count listing its studies:
botulinum toxin type A: first FDA approval 1991 (BOTOX COSMETIC), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 14 · Phase 4 12
First in 2003; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 808 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 70 across the 39 interventional studies. Of the 25 that completed or were terminated, 17 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merz Therapeutics GmbH, one of the names counted as Merz Pharma. Under that name alone:
Merz Therapeutics GmbH is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Merz Pharma has 2 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
4 of the studies testing botulinum toxin type A in Migraine Disorders that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05598723Phase 3Naval Medical Center Camp LejeuneBOTOX® vs. XEOMIN® for Chronic Migraine | 2027-02-24 |
| NCT07018700Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | 2027-03 |
| NCT07018713Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | 2027-03 |
| NCT07837570Assiut UniversityComparison of the Effectiveness of Greater Occipital Nerve and Supratrochlear Nerve Pulsed Radiofrequency Versus Botulinum Toxin Type A Injection in Chronic Migraine | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 39 studies testing botulinum toxin type A in Migraine Disorders, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this clinical trial, participants with chronic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections.
Trial details include:
Trial duration: 52 to 55 weeks;
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Placebo-controlled period + extension period: Xeomin injections at pericranial and cervical points (dose A)
Drug: Xeomin
Placebo-controlled period + extension period: Xeomin injections at pericranial and cervical point (dose B)
Drug: Xeomin
Placebo-controlled period: Placebo injections at pericranial and cervical points. Extension period: Xeomin injections at pericranial and cervical points (dose A)
Drug: Xeomin · Drug: Placebo
Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)
Also known as: IncobotulinumtoxinA, NT 201, Botulinum toxin type A (150 kiloDalton), free from complexing proteins
Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)
Change in monthly migraine days from baseline (28 days before baseline visit) to Month 6 (weeks 21 to 24 after first injection) - Dose A
Time frame: Baseline to month 6
Change in monthly migraine days from baseline (28 days before baseline visit) to Month 6 (weeks 21 to 24 after first injection) - Dose B
Time frame: Baseline to month 6
Change in monthly headache days from baseline (28 days before baseline visit) to Month 6 (weeks 21 to 24 after first injection) - Dose A
Time frame: Baseline to month 6
Change in monthly headache days from baseline (28 days before baseline visit) to Month 6 (weeks 21 to 24 after first injection) - Dose B
Time frame: Baseline to month 6
Change in monthly acute migraine medication days from baseline (28 days before baseline visit) to Month 6 (weeks 21 to 24 after first injection) - Dose A
Time frame: Baseline to month 6
Change in monthly acute migraine medication days from baseline (28 days before baseline visit) to Month 6 (weeks 21 to 24 after first injection) - Dose B
Time frame: Baseline to month 6
Change in frequency of migraine days from baseline (baseline monthly migraine days divided by 2) to two-week end-of-cycle periods (weeks 11 and 12 of Cycle 1 to 4)
Time frame: Baseline up to month 11
Percentage of participants who reported at least a 50% reduction in mean monthly migraine days from baseline (28 days before baseline visit) to Month 6 (weeks 21 to 24 after first injection)
Time frame: Baseline to month 6
Incidence of treatment-emergent adverse events (TEAEs) related to treatment as assessed by the investigator in the placebo-controlled period
Time frame: Month 6
Showing the first 100 of 111 sites across 13 countries. Choose a country and city above to see the rest.
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Mar 2027, 19 months after the start.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's planned 19 months is close to that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Oct 2027 → Mar 2027 and completion Mar 2028 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A